# FES BPET-DBT in Newly Diagnosed Breast Cancer

> **NCT05659797** · EARLY_PHASE1 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DEVICE:** BPET/DBT imaging
- **DRUG:** 18F-FES

## Key facts

- **NCT ID:** NCT05659797
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05659797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05659797, "FES BPET-DBT in Newly Diagnosed Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05659797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*